Achillion Pharmaceuticals News Releases http://ir.achillion.com/ Achillion Pharmaceuticals News Releases en Achillion Reports Positive Interim Data for ACH-4471 Phase 2 Combination Trial with Eculizumab at The New Era of Aplastic Anemia and PNH Meeting http://ir.achillion.com/news-releases/news-release-details/achillion-reports-positive-interim-data-ach-4471-phase-2 - ACH-4471 increased hemoglobin and nearly eliminated the need for transfusions in patients with PNH being treated with C5 inhibitor, eculizumab - BLUE BELL, Pa. , May 17, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated Fri, 17 May 2019 07:00:00 -0400 Achillion Pharmaceuticals News Releases 13931 Achillion Granted Twentieth Patent for Factor D Portfolio http://ir.achillion.com/news-releases/news-release-details/achillion-granted-twentieth-patent-factor-d-portfolio USPTO grants composition of matter patent for ACH-5548, Achillion’s 3rd clinical-stage asset BLUE BELL, Pa. , May 14, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) ), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families Tue, 14 May 2019 06:00:00 -0400 Achillion Pharmaceuticals News Releases 13921 Achillion Reports First Quarter 2019 Financial Results http://ir.achillion.com/news-releases/news-release-details/achillion-reports-first-quarter-2019-financial-results - PNH combo Phase 2 trial interim data to be presented May 17, 2019 - - C3G Phase 2 trials 24 patients enrolled as of May 2019 - - Next-generation ACH-5228 planned U.S. IND submission Q4:2019 - - Cash and securities of $254 million as of March 31, 2019 - BLUE BELL, Pa. Thu, 09 May 2019 06:00:00 -0400 Achillion Pharmaceuticals News Releases 13906 Achillion Announces Enrollment Milestone in Phase 2 Trials for C3 Glomerulopathy http://ir.achillion.com/news-releases/news-release-details/achillion-announces-enrollment-milestone-phase-2-trials-c3 - Enrolled 23 patients in ACH-4471 Phase 2 C3G six and 12-month clinical trials - - Targeting end-of-Phase 2 meeting with FDA in fourth quarter of 2019 - BLUE BELL, Pa. , April 03, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company Wed, 03 Apr 2019 06:00:00 -0400 Achillion Pharmaceuticals News Releases 13866 Achillion Announces Completion of Enrollment in Phase 2 PNH Combination Trial http://ir.achillion.com/news-releases/news-release-details/achillion-announces-completion-enrollment-phase-2-pnh - Completed enrollment in ACH-4471 Phase 2 PNH trial in combination with eculizumab - - Interim data to be released in May 2019 - - Targeting FDA end-of-Phase 2 meeting in second half of 2019 - BLUE BELL, Pa. , March 27, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. Wed, 27 Mar 2019 06:00:00 -0400 Achillion Pharmaceuticals News Releases 13856 Achillion to Present at the Barclays Global Healthcare Conference http://ir.achillion.com/news-releases/news-release-details/achillion-present-barclays-global-healthcare-conference-0 BLUE BELL, Pa. , March 08, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced that Joseph Truitt , President and Fri, 08 Mar 2019 06:00:00 -0500 Achillion Pharmaceuticals News Releases 13851 Achillion Reports Fourth Quarter and Full Year 2018 Financial Results http://ir.achillion.com/news-releases/news-release-details/achillion-reports-fourth-quarter-and-full-year-2018-financial - Phase 2 trial enrollment on schedule in PNH combo, interim data expected in Q2:2019 - - Phase 2 trial enrollment on schedule in C3G, 24 sites recruiting - - Next-generation factor D inhibitor ACH-5228 US IND anticipated in Q4:2019 - - Reduced 2018 net cash spend to $60 million , projecting $80 Thu, 07 Mar 2019 06:00:00 -0500 Achillion Pharmaceuticals News Releases 13836 Achillion Pharmaceuticals Expands Operations and Clinical Development into Philadelphia Area Office Market http://ir.achillion.com/news-releases/news-release-details/achillion-pharmaceuticals-expands-operations-and-clinical NEW HAVEN, Conn. , Feb. 21, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement mediated diseases, today announced the expansion into a second office Thu, 21 Feb 2019 06:00:00 -0500 Achillion Pharmaceuticals News Releases 13831 Achillion to Present at the SVB Leerink 8th Annual Global Healthcare Conference http://ir.achillion.com/news-releases/news-release-details/achillion-present-svb-leerink-8th-annual-global-healthcare NEW HAVEN, Conn. , Feb. 19, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced that Joseph Truitt , President and Tue, 19 Feb 2019 06:00:00 -0500 Achillion Pharmaceuticals News Releases 13826 Achillion Appoints Brian Di Donato as Chief Financial Officer http://ir.achillion.com/news-releases/news-release-details/achillion-appoints-brian-di-donato-chief-financial-officer NEW HAVEN, Conn. , Feb. 11, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced the appointment of Brian Di Donato Mon, 11 Feb 2019 06:00:00 -0500 Achillion Pharmaceuticals News Releases 13791